(Q38544813)

4 September 2017

1 reference

title

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). (English)

1 reference

4 September 2017

Veronika Malínková

1

0 references

Vladimír Kryštof

series ordinal

3

object named as

Vladimír Kryštof

1 reference

4 September 2017

Jakub Vylíčil

2

1 reference

PubMed ID

26161698

4 September 2017

language of work or name

English

0 references

publication date

10 July 2015

1 reference

Expert Opinion on Therapeutic Patents

4 September 2017

1 reference

4 September 2017

25

1 reference

4 September 2017

9

1 reference

4 September 2017

953-970

1 reference

Targeting cancer with small molecule kinase inhibitors

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

To cycle or not to cycle: a critical decision in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Targeting cyclin-dependent kinases in anti-neoplastic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

The history and future of targeting cyclin-dependent kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Cdk1 is sufficient to drive the mammalian cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1045414

10.1517/13543776.2015.1045414

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26161698